Clinical trial
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
NCT00442650 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00442650 |
|---|---|
| Title | Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Moderate to Severe Psoriasis |
| Intervention type | Drug |
| Interventions | Efalizumab |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Mar 2, 2007 |
| Last update posted | Nov 21, 2016 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: